Literature DB >> 22752606

Purinergic system ecto-enzymes participate in the thromboregulation of patients with indeterminate form of Chagas disease.

Viviane do Carmo Gonçalves Souza1, Karine B Schlemmer, Cristiano B Noal, Jeandre A S Jaques, Margarete D Bagatini, Victor C Pimentel, Luiz Felipe D Carli, Cláudio A M Leal, Juliana Fleck, Maria B Moretto, Maria R C Schetinger, Daniela B R Leal.   

Abstract

Chagas disease (CD) is a chronic and endemic illness caused by the parasite Trypanosoma cruzi. Microvascular disturbances play an important role in the progress of the disease. The purinergic signaling system participates in regulatory functions, such as immunomodulation, neuroprotection, and thromboregulation. This study aimed to investigate the activities of purinergic system ecto-enzymes present on the platelet surface and the platelet aggregation profile from patients with indeterminate form of Chagas disease (IFCD). Thirty patients diagnosed with IFCD and 30 healthy subjects were selected. Ecto-nucleoside triphosphate diphosphohydrolase (E-NTPDase), ecto-nucleotide pyrophosphatase/phosphodiesterase (E-NPP), ecto-5'-nucleotidase (E-5'-NT) and ecto-adenosine deaminase (E-ADA) activities were measured in platelets isolated from these individuals as well as the platelet aggregation. Results demonstrated an increase of 21 % in the E-NPP activity and 30 % in the E-5'-NT activity in IFCD group (P < 0.05); however, a decrease of 34 % in the E-ADA activity was determined in the same group (P < 0.001). A significant decrease of 12.7 % and 12.8 % in the platelet aggregation of IFCD group in two different concentrations of ADP (5 and 10 μM) was observed, respectively (P < 0.05). Increased E-NPP and E-5-NT activities as well as decreased E-ADA activity in platelets of patients with IFCD contributed to decrease platelet aggregation, suggesting that the purinergic system is involved in the thromboregulation process in these patients, since adenosine (the final product of ATP hydrolysis) has cardioprotective and vasodilator effects that prevent the clinical progress of the disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22752606      PMCID: PMC3486159          DOI: 10.1007/s11302-012-9322-7

Source DB:  PubMed          Journal:  Purinergic Signal        ISSN: 1573-9538            Impact factor:   3.765


  52 in total

1.  Differential effects of adenine nucleotide analogues on shape change and aggregation induced by adnosine 5-diphosphate (ADP) in human platelets.

Authors:  H S Park; S M Hourani
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

2.  Enzymes that hydrolyze adenine nucleotides in diabetes and associated pathologies.

Authors:  Gilberto Inácio Lunkes; Daniela Lunkes; Francieli Stefanello; André Morsch; Vera Maria Morsch; Cinthia Melazzo Mazzanti; Maria Rosa Chitolina Schetinger
Journal:  Thromb Res       Date:  2003-02-15       Impact factor: 3.944

3.  THE AGGREGATION OF BLOOD PLATELETS.

Authors:  G V BORN; M J CROSS
Journal:  J Physiol       Date:  1963-08       Impact factor: 5.182

4.  Microvascular changes as a cause of chronic cardiomyopathy in Chagas' disease.

Authors:  M A Rossi
Journal:  Am Heart J       Date:  1990-07       Impact factor: 4.749

5.  A direct colorimetric assay for Ca2+ -stimulated ATPase activity.

Authors:  K M Chan; D Delfert; K D Junger
Journal:  Anal Biochem       Date:  1986-09       Impact factor: 3.365

6.  [Pathological anatomy of hearts from asymptomatic Chagas disease patients dying in a violent manner].

Authors:  E R Lopes; E Chapadeiro; Z A Andrade; H O Almeida; A Rocha
Journal:  Mem Inst Oswaldo Cruz       Date:  1981 Apr-Jun       Impact factor: 2.743

7.  Hematological changes in mice experimentally infected with Trypanosoma cruzi.

Authors:  J E Cardoso; Z Brener
Journal:  Mem Inst Oswaldo Cruz       Date:  1980 Jul-Dec       Impact factor: 2.743

8.  Functional characterization of rat ecto-ATPase and ecto-ATP diphosphohydrolase after heterologous expression in CHO cells.

Authors:  P Heine; N Braun; A Heilbronn; H Zimmermann
Journal:  Eur J Biochem       Date:  1999-05

9.  NTPDase1 (CD39) controls nucleotide-dependent vasoconstriction in mouse.

Authors:  Gilles Kauffenstein; Annick Drouin; Nathalie Thorin-Trescases; Hélène Bachelard; Bernard Robaye; Pedro D'Orléans-Juste; François Marceau; Eric Thorin; Jean Sévigny
Journal:  Cardiovasc Res       Date:  2010-01-01       Impact factor: 10.787

10.  A new role for the A2b adenosine receptor in regulating platelet function.

Authors:  D Yang; H Chen; M Koupenova; S H Carroll; A Eliades; J E Freedman; P Toselli; K Ravid
Journal:  J Thromb Haemost       Date:  2010-01-21       Impact factor: 5.824

View more
  7 in total

1.  CR1-mediated ATP release by human red blood cells promotes CR1 clustering and modulates the immune transfer process.

Authors:  Mark I Melhorn; Abigail S Brodsky; Jessica Estanislau; Joseph A Khoory; Ben Illigens; Itaru Hamachi; Yasutaka Kurishita; Andrew D Fraser; Anne Nicholson-Weller; Elena Dolmatova; Heather S Duffy; Ionita C Ghiran
Journal:  J Biol Chem       Date:  2013-09-10       Impact factor: 5.157

2.  Purinergic ecto-enzymes participate in the thromboregulation in acute in mice infection by Trypanosoma cruzi.

Authors:  Guilherme M do Carmo; Pedro H Doleski; Mariângela F de Sá; Thirssa H Grando; Nathieli B Bottari; Daniela B R Leal; Lucas T Gressler; Ricardo E Mendes; Lenita M Stefani; Silvia G Monteiro; Aleksandro S Da Silva
Journal:  Mol Cell Biochem       Date:  2017-03-11       Impact factor: 3.396

Review 3.  Purinergic signalling in the gastrointestinal tract and related organs in health and disease.

Authors:  Geoffrey Burnstock
Journal:  Purinergic Signal       Date:  2013-12-04       Impact factor: 3.765

4.  Molecular Evidence of Adenosine Deaminase Linking Adenosine A2A Receptor and CD26 Proteins.

Authors:  Estefanía Moreno; Júlia Canet; Eduard Gracia; Carme Lluís; Josefa Mallol; Enric I Canela; Antoni Cortés; Vicent Casadó
Journal:  Front Pharmacol       Date:  2018-02-15       Impact factor: 5.810

5.  Increased levels of serum adenosine deaminase and increased risk of diabetic peripheral neuropathy in type 2 diabetes.

Authors:  Chao Yu; Lei Zhuang; Feng Xu; Li-Hua Zhao; Xiao-Hua Wang; Chun-Hua Wang; Li-Yan Ning; Xiu-Lin Zhang; Dong-Mei Zhang; Xue-Qin Wang; Jian-Bin Su
Journal:  Front Endocrinol (Lausanne)       Date:  2022-10-04       Impact factor: 6.055

6.  ADENOSINE DEAMINASE ACTIVITY AND SERUM C-REACTIVE PROTEIN AS PROGNOSTIC MARKERS OF CHAGAS DISEASE SEVERITY.

Authors:  Iván Darío Bravo-Tobar; Carlota Nello-Pérez; Alí Fernández; Nora Mogollón; Mary Carmen Pérez; Juan Verde; Juan Luis Concepción; Claudina Rodriguez-Bonfante; Rafael Bonfante-Cabarcas
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2015 Sep-Oct       Impact factor: 1.846

Review 7.  Therapeutic Perspectives of Adenosine Deaminase Inhibition in Cardiovascular Diseases.

Authors:  Barbara Kutryb-Zajac; Paulina Mierzejewska; Ewa M Slominska; Ryszard T Smolenski
Journal:  Molecules       Date:  2020-10-12       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.